These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 34405554)

  • 21. Use of real-world evidence for oncology clinical decision making in emerging economies.
    Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
    Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.
    Breckenridge AM; Breckenridge RA; Peck CC
    Br J Clin Pharmacol; 2019 Sep; 85(9):1874-1877. PubMed ID: 31290181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making.
    Katkade VB; Sanders KN; Zou KH
    J Multidiscip Healthc; 2018; 11():295-304. PubMed ID: 29997436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
    Hiramatsu K; Barrett A; Miyata Y;
    Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making.
    Solà-Morales O; Sigurðardóttir K; Akehurst R; Murphy LA; Mestre-Ferrandiz J; Cunningham D; de Pouvourville G
    Value Health; 2023 Apr; 26(4S):32-42. PubMed ID: 36870678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marketing Authorization Applications Made to the European Medicines Agency in 2018-2019: What was the Contribution of Real-World Evidence?
    Flynn R; Plueschke K; Quinten C; Strassmann V; Duijnhoven RG; Gordillo-Marañon M; Rueckbeil M; Cohet C; Kurz X
    Clin Pharmacol Ther; 2022 Jan; 111(1):90-97. PubMed ID: 34689339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions.
    Li P; Wang S; Chen Y
    Ther Innov Regul Sci; 2023 Nov; 57(6):1167-1179. PubMed ID: 37624556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
    Deverka PA; Douglas MP; Phillips KA
    Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes.
    Wilk N; Wierzbicka N; Skrzekowska-Baran I; Moćko P; Tomassy J; Kloc K
    Public Health; 2017 Apr; 145():51-58. PubMed ID: 28359391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union.
    Zou KH; Berger ML
    Bioengineering (Basel); 2024 Aug; 11(8):. PubMed ID: 39199742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reality check: Real-world evidence to support therapeutic development in hematologic malignancies.
    Derman BA; Belli AJ; Battiwalla M; Hamadani M; Kansagra A; Lazarus HM; Wang CK
    Blood Rev; 2022 May; 53():100913. PubMed ID: 35272867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model.
    Li M; Chen S; Lai Y; Liang Z; Wang J; Shi J; Lin H; Yao D; Hu H; Ung COL
    Front Med (Lausanne); 2021; 8():669509. PubMed ID: 34136505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
    Sievers H; Joos A; Hiligsmann M
    Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making.
    Baumfeld Andre E; Carrington N; Siami FS; Hiatt JC; McWilliams C; Hiller C; Surinach A; Zamorano A; Pashos CL; Schulz WL
    Clin Pharmacol Ther; 2022 Dec; 112(6):1172-1182. PubMed ID: 35213741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Use of Real-World Evidence and Data in Clinical Research and Postapproval Safety Studies.
    Lamberti MJ; Kubick W; Awatin J; McCormick J; Carroll J; Getz K
    Ther Innov Regul Sci; 2018 Nov; 52(6):778-783. PubMed ID: 29714579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World.
    McNair D; Lumpkin M; Kern S; Hartman D
    Clin Pharmacol Ther; 2022 Jan; 111(1):44-51. PubMed ID: 34655224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
    Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
    CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
    Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J
    Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance.
    Jaksa A; Wu J; Jónsson P; Eichler HG; Vititoe S; Gatto NM
    J Comp Eff Res; 2021 Jun; 10(9):711-731. PubMed ID: 33928789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.